Characteristics of Epstein-Barr virus-positive diffuse large B-cell lymphoma and the treatment progress in the era of new drugs
10.3760/cma.j.cn115356-20211214-00294
- VernacularTitle:EB病毒阳性弥漫大B细胞淋巴瘤的特点及新药时代治疗进展
- Author:
Jia LI
1
;
Jianpeng ZHOU
;
Ou BAI
Author Information
1. 吉林大学第一医院血液科，长春 130021
- Keywords:
Lymphoma, large B-cell, diffuse;
Epstein-Barr virus infections;
Immunotherapy
- From:
Journal of Leukemia & Lymphoma
2022;31(8):506-509
- CountryChina
- Language:Chinese
-
Abstract:
Epstein-Barr virus (EBV) -positive diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS), an aggressive B-cell lymphoma associated with chronic EBV infection, is an entity included in 2016 World Health Organization classification of lymphoid neoplasms. EBV-coding RNA (EBER) is expressed in the nucleus of these tumor cells. EBV -positive DLBCL can be mostly found in the elderly who have poor immunochemotherapy effect and short overall survival time, and this poor prognosis is inconsistent with international prognostic index (IPI) stratification. CD30 and programmed death 1/programmed death ligand 1 are expected to be the potential prognostic indicators and therapeutic targets. This paper reviews the relationship between EBV-positive DLBCL-NOS and EBV infection, clinicopathological characteristics, prognostic evaluation factors and treatment in the era of new drugs.
